Insider · CIK 0001780408
KKR Genetic Disorder L.P.
Files at BBIO (BridgeBio Pharma, Inc.). First filing Mar 7, 2025, latest May 14, 2025.
KKR Genetic Disorder L.P. files SEC Form 4 as 10% owner at BBIO (BridgeBio Pharma, Inc.). Since Mar 7, 2025, KKR Genetic Disorder L.P. has reported 0 open-market buys worth $0 and 2 open-market sells worth $403M, the latest filed on May 14, 2025.
A track record needs three past buys with six months of prices behind them; KKR Genetic Disorder L.P. has 0, so none is measured yet.
The newest scored trade: sold $205M of BBIO on May 12, 2025, filed May 14, 2025, scored 62 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BBIO: BridgeBio Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | BridgeBio Pharma, Inc. | $205M 6,000,000 shares | -31% | +60% from low-7% from high | |
| 57Moderate | BridgeBio Pharma, Inc. | $198M 6,000,000 shares | -24% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 12, 2025 | BBIO BridgeBio Pharma, Inc. | 6,000,000 3.16% of outstanding | $214M | May 12, 2025 | $210M |
| Mar 5, 2025 | BBIO BridgeBio Pharma, Inc. | 6,000,000 3.15% of outstanding | $210M | Mar 5, 2025 | none |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 12, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -6,000,000 | $34.20 | $205M | 13,260,971 | May 14, 2025 |
| Mar 5, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -6,000,000 | $32.96 | $198M | 19,260,971 | Mar 7, 2025 |
Questions about KKR Genetic Disorder L.P.
Answered from the filings on this page, as of the latest one.
Is KKR Genetic Disorder L.P. buying or selling?
Not in the last 12 months. KKR Genetic Disorder L.P.'s latest open-market trade on SEC Form 4 was sold $205M of BBIO on May 12, 2025.
How did KKR Genetic Disorder L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and KKR Genetic Disorder L.P. has 0.
Where does KKR Genetic Disorder L.P. file Form 4?
KKR Genetic Disorder L.P. has filed Form 4 at BBIO (BridgeBio Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.